jose g. guillem, md, mph department of surgery memorial sloan kettering cancer center

22
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering Cancer Center Great Debates & Updates in GI Malignancies March 28-29, 2014

Upload: odelia

Post on 16-Jan-2016

111 views

Category:

Documents


0 download

DESCRIPTION

Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease. Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering Cancer Center. Great Debates & Updates in GI Malignancies March 28-29, 2014. Case. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Defining the Colorectal Surgeons role in patients with colorectal cancer and

limited metastatic disease

Jose G. Guillem, MD, MPH

Department of Surgery

Memorial Sloan Kettering Cancer Center

Great Debates & Updates in GI Malignancies

March 28-29, 2014

Page 2: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Case

• 58M with 10lb weight loss, rectal pain/tenesmus, bleeding

• PMH: unremarkable

• DRE: palpable tethered mass with distal margin at 8cm from AV, 5cm above ring

• Flex sig: circumferential, ulcerated bulky near-obstructing mass

• CT scan: liver metastases

Page 3: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Stage IV Rectal Cancer

Page 4: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Stage IV Rectal Cancer

Page 5: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Management Options in Metastatic Rectal Ca

• Systemic Chemotherapy alone

• Stent and Chemotherapy

• Divert and Chemotherapy

• Resect and Chemotherapy

• Chemotherapy and Resect

• Chemotherapy, Chemoradiation and Resect

Page 6: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Central Issues

• Benefit of surgical resection over stent/diversion alone– Alleviation of bleeding, pain, tenesmus

• Morbidity and mortality of resection

• Delay in administering systemic chemo

Page 7: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Metastatic Rectal Cancer

• Bulky symptomatic primary with extensive liver mets

• Bulky symptomatic primary with limited liver metastases

• Non-bulky asymptomatic primary with extensive liver mets

• Non-bulky asymptomatic primary with limited liver mets

Page 8: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

• 33 successful stents out of 34 pts (97%)

Palliation of malignant rectal obstruction with self-expanding metal stents

Hünerbein M et al. Surgery. 2005

Overall, 18% required surgery because of stent complications

Stent migration x 3Intractable pain x 2Incomplete stent expansion x 1Incontinence x 1

Rectovesical fistula x 1Incontinence x 1

Page 9: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Malignant rectal obstruction within 5cm of the anal verge: is there a role for

expandable metallic stent placement?• Group A: obstruction ≤ 5cm from AV• Group B: obstruction > 5cm from AV• Tx: PU or PTFE covered retrievable stents

Song HY et al. Gastrointest Endosc. 2008

Page 10: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease

• N=80 with rectal CA resection without radiotherapy

• 12 (15%) surgical complications– 1 death– 4 reoperations

• 15 (19%) required colostomy at initial resection

• 5 (6%) local recurrences– Median time to local recurrence = 14 mos

• Median survival = 25 mos– 11 patients died within 6 mos

Nash GM et al, Annals of Surg Oncol, 2002.

Page 11: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

• <50% liver replacement

• Complete or near complete response of primary to first chemo regimen

• Able to receive subsequent aggressive, post-operative chemo

Radical resection of primary in stage IV rectal cancer patients – who benefits?

Nash GM et al, Annals of Surg Oncol, 2002.

Page 12: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Would modern, combination chemotherapy obviate the need

for resection of the primary rectal cancer?

Page 13: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Combination chemotherapy without surgery as initial treatment

• 233 patients with synchronous metastatic colorectal cancer

• 93% of patients who received upfront chemotherapy never required palliative surgery for primary tumor

• 89% required no direct symptomatic management for intact primary tumor

Poultsides et al. J Clin Oncol 2009

Page 14: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Combination chemotherapy without surgery as initial treatment

Poultsides et al. J Clin Oncol 2009

Rectal Primary(n=78)

No Emergent Intervention

85% (n=66)

Emergent Primary-Directed Intervention

15% (n=12)

Page 15: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Would modern, combination chemotherapy obviate the need for resection of the primary

rectal cancer?

In some, initially yes, but if combinational chemotherapy converts unresectable liver mets to resectable, in the long run we may

need to address the primary rectal cancer in more.

Page 16: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Anastomotic leak following low anterior resection in stage IV rectal cancer is associated

with poor survival

• N = 123 pts resected with curative intent

Smith JD et al. Ann Surg Oncol. 2013

Overall leak rate 6.5%

3y OS 72%

3y OS 32%

Factors identified as significant in univariate analysis for Overall Survival (OS)

Multivariate analysis for overall survival

Page 17: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Management Dilemma

Morbidity

Efficacy

Page 18: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Treatment PathwayStage IV Rectal Cancer

with Synchronous Liver MetastasesObstructed Non-obstructed

Resect Stent Divert Extrahepatic Metastases

No Extrahepatic Metastases

ChemotherapyResectable Liver Metastases Nonresectable Liver Metastases

Isolated, Single, or Peripheral

Bilobar or Multiple

ChemotherapyResect Liver

Resectable Rectum Nonresectable Rectum

Chemoradiation TherapyResect Rectum

Resect metastases and rectumif possible

Page 19: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Treatment PathwayStage IV Rectal Cancer

with Synchronous Liver MetastasesObstructed Non-obstructed

Resect Stent Divert Extrahepatic Metastases

No Extrahepatic Metastases

ChemotherapyResectable Liver Metastases Nonresectable Liver Metastases

Isolated, Single, or Peripheral

Bilobar or Multiple

ChemotherapyResect Liver

Resectable Rectum Nonresectable Rectum

Chemoradiation TherapyResect Rectum

Resect metastases and rectumif possible

Synchronous vs. Staged

Systemic vs. HAI

Chemotherapy first, then radiation?Short-course vs. long-course?

When, and in what order?

Page 20: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Management Options in Unresectable Metastatic Rectal Ca

• If symptoms of primary (bleeding, pain, tenesmus) are formidable and volume of liver mets limited (<50%) : Resect primary

• If patient cannot tolerate rectal resection: Laparoscopic diversion

• Defer stenting rectal cancer as last resort

Page 21: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Metastatic Rectal CA – Chemotherapy, Radiation, Divert, Stent or Resect First?

• Multidisciplinary approach throughout• Colorectal surgeon:

Bulk/lumen of primary, CRM, sphincter preservation, co-morbidities?

• Liver surgeon

Resectability of mets, status of liver parenchyma, co-morbidities

• Medical/Radiation Oncologist

Co-morbidities, volume:primary vs mets

Page 22: Jose G. Guillem, MD, MPH  Department of Surgery Memorial Sloan Kettering Cancer Center

Metastatic Rectal Cancer – Chemotherapy, Radiation, or Surgery First?

Individualize, Individualize, Individualize